Sequence: WEKLAKALAKALAKHLAKALAKALKA-NH2
| Experiment Id | EXP001416 |
|---|---|
| Paper | Mitochondrial transgene expression via an artificial mitochondrial DNA vector in cells from a patien |
| Peptide | KALA |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | Surface display: STR-KALA 10 mol% of total lipids |
| Rna Concentration | 0.4 µg pDNA per well (24-well plate); 3 h in serum-free medium then 21 h in 10% serum |
| Mixing Ratio | Protamine condensation N/P=2.3; final DNA concentration for packaging 35 µg/mL; lipid envelope DOPE/SM/CHEMS = 9:2:1 (molar ratio) lipid envelope around protamine-condensed pDNA; STR-KALA 10 mol% of total lipids |
| Formulation Format | KALA-MITO-Porter (liposome-based MITO-Porter modified with STR-KALA) |
| Formulation Components | Protamine-condensed pDNA core + lipid envelope (DOPE/SM/CHEMS = 9:2:1 (molar ratio) lipid envelope around protamine-condensed pDNA) + STR-KALA (10 mol%) |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HeLa (human cervix carcinoma) |
| Animal Model | |
| Administration Route | |
| Output Type | Mitochondrial transgene expression (NanoLuc luciferase activity, RLU/mg protein) |
| Output Value | |
| Output Units | |
| Output Notes | Mitochondrial transfection with KALA-MITO-Porter yielded luciferase activity; pCMV-mtLuc(CGG)[hND4] gave the highest expression among tested promoter variants. |
| Toxicity Notes | |
| Curation Notes |